News

The RAN has recently signed a 3-year $25M agreement with the Celgene Corporation to develop next-generation, antibody-based cancer therapies with the option to enter into future license agreements. Collaboration will focus on novel high value cancer targets. Besides supporting the high throughput antibody generating pipelines, this agreement will enable setting up robotics for a battery of state of the art cell based assays. The capacity that can be achieved with regard to antibody generation and target validation is unmatched by any similar facility in the world. 

We have recently updated the antibody catalog

Advanced robotic system designed to screen thousands of recombinant antibodies without human intervention. Video shows sequence of ELISA and colony picking schedules executed on the same system. Portions of this video has been speed up by a factor of 2.

A major strength of the management structure is the proven record of the leadership to work in unison to manage large, complex and intellectually challenging programs. In fact, several of the team have successfully managed projects in industry that were significantly larger and more complex than what is proposed here. Further, the RAN leadership team is linked through a unique history of collaborative interaction that spans over two decades.